Zobrazeno 1 - 10 of 47 pro vyhledávání: '"Hypertension, Pulmonary/drug therapy"'
1
Akademický článek
Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension
Autor: Caio Julio Cesar dos Santos Fernandes, Jaquelina Sonoe Ota-Arakaki, Frederico Thadeu Assis Figueiredo Campos, Ricardo de Amorim Correa, Marcelo Basso Gazzana, Carlos Vianna Poyares Jardim, Fábio Biscegli Jatene, Jose Leonidas Alves Junior, Roberta Pulcheri Ramos, Daniela Tannus, Carlos Teles, Mario Terra Filho, Daniel Waetge, Rogerio Souza
Publikováno v: Jornal Brasileiro de Pneumologia, Vol 46, Iss 4 (2022)
ABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious and debilitating disease caused by occlusion of the pulmonary arterial bed by hematic emboli and by the resulting fibrous material. Such occlusion increases vascular resistan
Externí odkaz: https://doaj.org/article/8edcdba9ddce4e59bd4ed600e050e18d
Zobrazit plný text záznamu
2
Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension
Autor: Ricardo de Amorim Corrêa, Fabio Biscegli Jatene, Caio Julio Cesar dos Santos Fernandes, Rogério Souza, Daniel Waetge, Mário Terra Filho, Jose Leonidas Alves Junior, Marcelo Basso Gazzana, Roberta Pulcheri Ramos, Carlos Jardim, Frederico Thadeu Assis Figueiredo Campos, Daniela Tannus, Jaquelina S. Ota-Arakaki, Carlos Teles
Publikováno v: Jornal Brasileiro de Pneumologia v.46 n.4 2020
Jornal Brasileiro de Pneumologia
Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron:SBPT
Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious and debilitating disease caused by occlusion of the pulmonary arterial bed by hematic emboli and by the resulting fibrous material. Such occlusion increases vascular resistance and, c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68af788a1bbe4e768786ba326573d684
https://pubmed.ncbi.nlm.nih.gov/35766678
Zobrazit plný text záznamu
3
Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
Autor: Giuseppina Milano, Antonio F. Corno, Coline Nydegger, Ludwig K. von Segesser, Maurice Beghetti, Michele Samaja
Publikováno v: Cardiovascular Drugs and Therapy
Cardiovascular drugs and therapy, vol. 33, no. 4, pp. 407-414
Cardiovascular Drugs and Therapy, Vol. 33, No 4 (2019) pp. 407-414
Purpose In pulmonary hypertension (PH), hypoxia represents both an outcome and a cause of exacerbation. We addressed the question whether hypoxia adaptation might affect the mechanisms underlying PH alleviation through phosphodiesterase-5 (PDE5) inhi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed473909655b9dee0f381932d76ce1e
https://pubmed.ncbi.nlm.nih.gov/31264002
Zobrazit plný text záznamu
4
Evaluation of Macitentan in Patients With Eisenmenger Syndrome
Autor: Gatzoulis, M.A., Landzberg, M., Beghetti, M., Berger, R.M., Efficace, M., Gesang, S., He, J., Papadakis, K., Pulido, T., Galiè, N.
Publikováno v: Circulation, vol. 139, no. 1, pp. 51-63
Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::bfe35a2b36e413c7337ccb8cf1df5ac1
https://serval.unil.ch/notice/serval:BIB_2B3253EE0026
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3
Autor: Berger, Rolf M. F., Gehin, Martine, Beghetti, Maurice, Ivy, Dunbar, Kusic‐Pajic, Andjela, Cornelisse, Peter, Grill, Simon, Bonnet, Damien
Publikováno v: British Journal of Clinical Pharmacology, 83(8), 1734-1744. Wiley
British Journal of Clinical Pharmacology, Vol. 83, No 8 (2017) pp. 1734-1744
British journal of clinical pharmacology, vol. 83, no. 8, pp. 1734-1744
British Journal of Clinical Pharmacology
The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg -1 twice daily (b.i.d.) to 2 mg kg -1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::90514a22b48a6bcdd5ac2f77a188bbfc
https://research.rug.nl/en/publications/d33726ef-3dc0-40d5-93b1-d6dbb204e73c
Zobrazit plný text záznamu
7
Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
Autor: Maurice Beghetti, Min Zhang, Andrzej Rudziński
Publikováno v: BMC cardiovascular disorders, vol. 17, no. 1, pp. 177
BMC Cardiovascular Disorders, Vol. 17, No 1 (2017) P. 177
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, Vol 17, Iss 1, Pp 1-9 (2017)
Background Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-nai
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9cbdd3b92fb7586d13959facc75acb
https://serval.unil.ch/resource/serval:BIB_A5F1C22FB19B.P001/REF.pdf
Zobrazit plný text záznamu
8
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
Autor: Xavier Jaïs, Jasper Dingemanse, Andjela Kusic-Pajic, Adele Morganti, D. Dunbar Ivy, Damien Bonnet, Sheila G. Haworth, Ingram Schulze-Neick, Rudolphus Berger, Robyn J. Barst, Alain Fraisse, Nazzareno Galiè, Maurice Beghetti, Philippe Acar
Publikováno v: British Journal of Clinical Pharmacology, Vol. 68, No 6 (2009) pp. 948-955
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 68(6), 948-955. Wiley
center dot Exposure to bosentan was lower in paediatric pulmonary arterial hypertension (PAH) patients treated with the marketed adult formulation at a dose of about 2 mg kg-1 when compared with adult PAH patients.center dot In healthy adult subjects
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28746de409f1cb35e85ac12beefc9b1
https://doi.org/10.1111/j.1365-2125.2009.03532.x
Zobrazit plný text záznamu
9
The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
Autor: Jean-Luc Vachiery, Anthony P. Davenport
Publikováno v: European respiratory review, 18 (114
Endothelial cells regulate vascular tone largely by the actions of endothelin-1. Endothelin-1 is a potent vasoconstrictor, with effects that are dependent on the receptors to which it binds as well as their location. Endothelin-1 dysregulation is imp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e3ad33011339bb66076a3d8650430ba
https://doi.org/10.1183/09059180.00005709
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje